Cite
HARVARD Citation
Ruggeri, M. et al. (2019). Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy. Expert review of pharmacoeconomics & outcomes research. pp. 363-374. [Online].